Related Experiment Video

Updated: Sep 21, 2025

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

7.6K

MicroRNAs as therapeutic targets in cardiovascular disease

Bernhard Laggerbauer1, Stefan Engelhardt1,2

  • 1Institute of Pharmacology and Toxicology, Technical University of Munich (TUM), Munich, Germany.

The Journal of Clinical Investigation
|June 1, 2022
PubMed

Insights

MicroRNAs show promise as drug targets for cardiovascular diseases, overcoming limitations of current treatments. Research is advancing microRNA therapeutics from the lab to clinical trials.

Area of Science:

  • Biomedical Science
  • Molecular Biology
  • Cardiovascular Research

Background:

  • MicroRNAs (miRNAs) are key regulators of gene expression implicated in various diseases.
  • Conventional pharmacotherapy for cardiovascular diseases has limitations.
  • miRNA research has identified them as potential therapeutic targets.

Purpose of the Study:

  • To review the current status of microRNAs as therapeutic targets in cardiovascular medicine.
  • To highlight advances in miRNA identification, characterization, and manipulation.
  • To discuss the clinical translation and future perspectives of miRNA-based therapies.

Main Methods:

  • Literature review of preclinical and clinical studies on miRNAs in cardiovascular diseases.
  • Analysis of recent advances in miRNA discovery and functional characterization.
  • Evaluation of miRNA-based drug development and clinical trial progress.

Main Results:

  • Significant progress has been made in identifying and characterizing cardiovascular miRNAs.
  • miRNA-based drugs have advanced into preclinical and clinical testing phases.
  • The potential for miRNA therapeutics to address limitations of conventional treatments is evident.

Conclusions:

  • MicroRNAs represent a promising frontier for novel cardiovascular therapeutics.
  • Continued research and development are crucial for clinical application.
  • Overcoming challenges in delivery and specificity will be key to successful translation.
Keywords:
CardiologyCardiovascular diseaseNoncoding RNAsTherapeutics

More Related Videos

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting11:37

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting

Published on: June 18, 2018

6.7K
Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization08:22

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

8.2K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
528
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
389